The novel oral selective estrogen receptor (ER) degrader giredestrant significantly reduced the risk of invasive disease ...

A recent study found that breast cancer–specific survival in patients with invasive lobular carcinoma was inferior compared to patients with invasive ductal carcinoma. A recent study found that breast ...

Sichun Yang, PhD, a member of Case CCC's Molecular Oncology Program, and Alberto Montero, MD, a Developmental Therapeutics Program member, are looking for patient advocates for a follow-up study to ...

While researchers work to improve lobular breast cancer screening, innovative treatments are improving outcomes for patients with the condition, which is diagnosed in more than 40,000 Americans each ...

Rates of one type of breast cancer — invasive lobular carcinoma — have been rising in the United States more than three times faster than those of all other breast cancers combined over the past ...

A fast-rising form of breast cancer that's harder to detect on mammograms now makes up more than one in ten cases in the United States, according to a new report from the American Cancer Society (ACS) ...

Lobular breast cancer rates increased 2.8 percent per year over the past decade, compared with a 0.8 percent annual increase for all other breast cancers. Lobular breast cancer grows in a linear ...

Dr. Melvin Silverstein answers the question: 'What's Invasive Ductal Carcinoma?' — -- Question: What is invasive ductal carcinoma? Answer: Invasive ductal carcinoma is the most common type of ...

Genomic alterations (GAs) associated with durability of benefit from trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1) and sacituzumab govitecan (SG) in metastatic breast cancer (MBC).